肺高压相关生物标记物研究进展  

Recent advances of biomarkers associated with pulmonary hypertension

作　　者：丁文秋[1] 孔辉[1] 解卫平[1] 王虹[1] 

机构地区：[1]南京医科大学第一附属医院呼吸科,210029

出　　处：《国际呼吸杂志》2015年第14期1101-1104,共4页International Journal of Respiration

基　　金：国家自然科学基金（81273571）;江苏省人事厅六大人才高峰（2008074）;江苏省科技厅科技支撑计划（BE2011801）;江苏省呼吸病临床医学研究中心（BL2012012）

摘　　要：肺高压是多种因素引起的肺血管疾病，它的预后差，最终引起右心功能衰竭而致患者死亡。近年来，发现肺高压相关的生物标记物可协助临床医师诊断肺高压，评估肺高压严重性、治疗效果及判断预后。本文就肺高压相关生物标记物作一综述。Pulmonary hypertension is a pulmonary vascular disease of heterogeneous origins,which is associated with a poor prognosis, ultimately leads to right heart failure, and causes the patients death. In recent years, an increasing number of biomarkers have been described in pulmonary hypertension and which may assist the clinician in diagnosis and the assessment of disease severity, response to treatment and the prognosis. This article reviews the biomarkers associated with pulmonary hypertension.

关 键 词：肺高压 生物标记物 内皮素 钠尿肽 

分 类 号：R730.43[医药卫生—肿瘤]